《2011AHPBA美國肝細(xì)胞癌療前評估》內(nèi)容簡介：

    Staging of hepatocellular carcinoma （HCC） is complex and relies on multiple factors including tumorextent and hepatic function. No single staging system is applicable to all patients with HCC. The stagingof the American Joint Committee on Cancer / International Union for Cancer Control should be used topredict outcome following resection or liver transplantation.

    《2011AHPBA美國肝細(xì)胞癌療前評估》內(nèi)容預(yù)覽：

    The Barcelona Clinic Liver Cancer scheme isappropriate in patients with advanced HCC not candidate for surgery. Dual phase computed tomographyor magnetic resonance imaging can be used for pretreatment assessment of tumor extent but theaccuracy of these methods remains poor to characterize <1 cm lesions. Assessment of tumor responseshould not rely only on tumor size and new imaging methods are available to evaluate response to therapyin HCC patients. Liver volumetry is part of the preoperative assessment of patients with HCC candidatefor resection as it reflects liver function. Preoperative portal vein embolization is indicated in patients withsmall future liver remnant （ 20% in normal liver; 40% in fibrotic or cirrhotic liver）。 Tumor size is not acontraindication to liver resection. Liver resection can be proposed in selected patients with multifocalHCC. Besides tumor extent, surgical resection of HCC may be performed in selected patients withchronic liver disease.

    點擊下載***：《2011AHPBA美國肝細(xì)胞癌療前評估》